The Lambert Initiative will examine Avecho’s low-dose CBD product in two further clinical trials later this year. Researchers will target novel indications not previously associated with CBD using the company’s low-dose, soft-gel capsules. The indications, which were not disclosed, emerged following pre-clinical and early-stage studies conducted by Lambert.
Source: Cannabiz